News and Trends 7 Feb 2023 Antibody candidate for treating serious liver disease There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. However, a new study led by researchers from Karolinska Institutet in Sweden has identified a drug candidate for the treatment of fatty liver. The preclinical study, published […] February 7, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 Is Copenhagen the world capital of life science? Denmark’s leading life science companies, public foundations, municipalities, universities and hospitals will work together to position Copenhagen as the world capital of life science through the newly-launched Copenhagen Life Science partnership. Tackling obesity is the first step in this public-private partnership. In 2022, the Danish government invested 82 million DKK ($11.7 million) to strengthen and […] January 17, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What’s in store for biotech in 2023? Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […] January 11, 2023 - 14 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Lifesciences and biotech in 2023 A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging year—at least financially—in biotech. Do you see those trends continuing? Although we see overall sentiments to invest in biotech turning positive in 2023 after a […] January 11, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2022 Watch: Aphaia Pharma interview Aphaia Pharma is a Zug, Switzerland, headquartered clinical-stage biopharmaceutical company. It harnesses proprietary precision-targeted drug delivery technology to restore endogenous hormone release in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia Pharma’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release […] December 21, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Pfizer diabetes and obesity study triggers Sosei Heptares windfall Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […] December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2022Beyond Biotech podcast 16: Adocia, Omnio, Phenomix Sciences, Tridek-One This week, we have four guests: Olivier Soula, deputy-CEO and director of R&D at Adocia; Ulrika Norin, CEO of Omnio; Mark Bagnall, CEO of Phenomix Sciences; and Laurence de Schoulepnikoff, CEO of Tridek-One. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored […] September 30, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Rivus Pharmaceuticals raises $132M for treatment of obesity and cardio-metabolic disorders Rivus Pharmaceuticals Inc. has completed a $132 million series B financing round. It was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. The financing will further support clinical advancement of lead candidate HU6, a first-in-class controlled metabolic accelerator (CMA) designed […] September 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 16 Sep 2022 Strategic collaboration for drug to treat NASH, obesity and diabetes announced A conditional and exclusive license agreement to develop and commercialize a drug to treat nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes has been agreed. NeuroBo Pharmaceuticals and Dong-A ST Co., announced their strategic collaboration today (September 16) for DA-1241 and DA-1726 which are currently being evaluated for treatment. DA-1241 is a novel G-Protein-Coupled Receptor […] September 16, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 NTU Singapore opens microbiome research center to study obesity and chronic diseases Nanyang Technological University, Singapore (NTU Singapore) has created the Centre for Microbiome Medicine – a research facility that aims to improve human health and find new ways to treat diseases by leveraging the microbiome, which are naturally present microorganisms that play a vital role in our wellbeing. The research centre at NTU Singapore’s Lee Kong […] September 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Innovent starts trial of mazdutide in Chinese adults with obesity Innovent Biologics, Inc. says the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical trial of mazdutide, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with obesity. This randomized, double-blinded, placebo-controlled study was designed to evaluate the efficacy and safety of mazdutide […] September 6, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2022 Swiss Startup Signs on with Novo Nordisk to Discover Obesity Treatments The Swiss startup EraCal Therapeutics has signed a research partnership with the Danish pharmaceutical giant Novo Nordisk to search for treatments controlling food intake and other factors contributing to obesity. Under the joint project, EraCal and Novo Nordisk will research targets for obesity treatments by identifying molecules that can control appetite and improve metabolic health. […] January 17, 2022 - 3 minutesmins - By Dan Samorodnitsky Share WhatsApp Twitter Linkedin Email